However, tumor‐specific CTLs from the KRAS mutant versus wild‐type tumor tissues had matched expression levels of the death receptors, including Fas, TNFR2, and TRAILER (Figure 4N,O), suggesting that the differential AICD sensitivity is not controlled by the death receptor expression, but rather is determined by other factors. This evidence concerns the gene KRAS and neoplasm.